The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

被引：0
作者：
Charlotte Louise Maria Krieckaert
Geertje Margret Bartelds
Willem Frederik Lems
Gerrit Jan Wolbink
机构：
[1] Jan van Breemen Institute,Department of Rheumatology
[2] VU Medical Center,Department of Rheumatology
来源：
Arthritis Research & Therapy | / 12卷
关键词：
Infliximab; Adalimumab; Crohn Disease; Therapeutic Monoclonal Antibody; Biological Therapeutics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Therapeutic monoclonal antibodies have revolutionized the treatment of various inflammatory diseases. Immunogenicity against these antibodies has been shown to be clinically important: it is associated with shorter response duration because of diminishing concentrations in the blood and with infusion reactions. Concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoid arthritis, Crohn disease, and juvenile idiopathic arthritis. The occurrence of adverse events does not increase when immunomodulators are added to therapeutic antibodies. The mechanism whereby methotrexate and azathioprine influence immunogenicity remains unclear. Evidence-based consensus on prescribing concomitant immunomodulators is needed.
引用
收藏
相关论文
共 281 条
[1]  
Emi AN(2010)Immunogenicity of anti-TNF-alpha agents in autoimmune diseases Clin Rev Allergy Immunol 38 82-89
[2]  
de Carvalho JF(2006)Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis Rheum 54 3782-3789
[3]  
Artur Almeida SC(2000)Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 1594-1602
[4]  
Bonfa E(1998)Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1552-1563
[5]  
Bendtzen K(2009)Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 68 1739-1745
[6]  
Geborek P(2006)Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum 54 711-715
[7]  
Svenson M(2007)Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 66 921-926
[8]  
Larsson L(2008)Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study Mod Rheumatol 18 252-262
[9]  
Kapetanovic MC(2004)Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 508-516
[10]  
Saxne T(2003)Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 601-608
12345678910